Skip To Main Content

Help Open Up the Possibility of Next-Level Relief: When Patients Aged ≥12 Years with CSU Remain Symptomatic Despite H1 Antihistamine Therapy, Start XOLAIR

When the cycle of chronic spontaneous urticaria (CSU) symptoms persists despite H1 antihistamine treatment, consider XOLAIR earlier. XOLAIR was studied in patients who experienced itch and hives for ≥8 consecutive weeks prior to enrollment despite the use of H1 antihistamines.34,35

XOLAIR has been shown to reduce mean weekly itch severity and mean weekly hive count scores in appropriate CSU patients 12 years and older uncontrolled on H1 antihistamines.5 Use the links below to learn more:

Mean Weekly Itch Data 
Mean Weekly Hive Data 
Complete Relief Data

See additional information for patient baseline characteristics. Please see full safety information.

Mean Weekly Itch Data

Feeling is Believing: XOLAIR Delivered Significant Itch Relief

In Studies 1 & 2:

Study Designs

The safety and efficacy of XOLAIR for the treatment of CSU were assessed in 2 placebo-controlled, multiple-dose clinical studies of 24 weeks’ duration (CSU Study 1; N=319) and 12 weeks’ duration (CSU Study 2; N=322). Patients received XOLAIR 300 mg, 150 mg, 75 mg, or placebo in addition to their baseline level of H1 antihistamine therapy. The 75-mg dose is not approved for use.1 Concomitant CSU treatments other than H1 antihistamines were not allowed during the study.1,34

Demonstrated Reductions in Mean Weekly Itch Severity Score Throughout Treatment

Demonstrated reductions in mean weekly itch severity score throughout treatment5,34
Graph showing demonstrated Reductions in Mean Weekly Itch Severity Score throughout treatment

Study 1: Change from baseline in mean weekly itch severity score at Week 12 (N=241)5,34*
Similar results were seen in Study 2.

 

Study 2 Confirms Significant Relief

 71% and 56% reductions in mean weekly itch severity score from baseline at week 12 were demonstrated for XOLAIR 300 mg and 150 mg, respectively, vs 36% for the active control group.10*†

XOLAIR reduced mean weekly itch severity scores at Week 12 from baseline, which was the primary endpoint (XOLAIR 300 mg, -9.8 from 13.7; XOLAIR 150 mg, -8.1 from 14.2; placebo, -5.1 from 14.0).35

The difference in LS mean vs active control was -4.8 for XOLAIR 300 mg (P<0.001; 95% Cl: -6.5, -3.1) and -3.0 for XOLAIR 150 mg (P<0.01; 95% Cl: -4.9, -1.2)35

Study Designs

Itch severity: During Studies 1 and 2, the itch severity score was measured twice a day (AM and PM) on a scale of 0 (none) to 3 (severe). The daily itch severity score was the average of the morning and evening scores, and the weekly itch severity score (0-21) was the sum of the daily itch severity scores over 7 days. 5

*All patients received their dose of study drug or placebo in addition to stable doses of their prerandomization H1 antihistamine. 5

The weekly itch severity score was calculated for each patient at each week. The mean change from baseline (the primary efficacy analysis) and the mean percentage change in weekly itch severity score were calculated for each treatment group for comparison vs active control at week 12 (the primary efficacy analysis time point). 5,35

Cl=confidence interval; LS=least squares; q4w=every 4 weeks.

Mean Weekly Hive Data

Seeing is Believing: XOLAIR Delivered Significant Relief from Hives

In Studies 1 & 2:

Study Designs

The safety and efficacy of XOLAIR for the treatment of CSU was assessed in 2 placebo-controlled, multiple-dose clinical studies of 24 weeks’ duration (CSU Study 1; N=319) and 12 weeks’ duration (CSU Study 2; N=322). Patients received XOLAIR 300 mg, 150 mg, 75 mg, or placebo in addition to their baseline level of H1 antihistamine therapy. The 75-mg dose is not approved for use.1 Concomitant CSU treatments other than H1 antihistamines were not allowed during the study.1,35,36

Demonstrated Reductions in Mean Weekly Hive Count Score From Baseline at Week 125

Weekly Hive Count Score in Study 11,5,36*†
Reductions in Mean Weekly Hive Count Score. Baseline, 300mg 67% reduction, 150mg 50% reduction, placebo 25% reduction.

Study 1: Change from baseline in mean weekly hive count score at Week 12 (N=241).*

Similar Results Were Seen in Study 25,31

74% and 57% reductions in mean weekly hive count score from baseline at week 12 were demonstrated for XOLAIR 300 mg and 150 mg, respectively, vs 31% for the active control group.10‡

XOLAIR reduced mean weekly hive count scores at Week 12 from baseline (XOLAIR 300 mg, 12.0 from 15.8; XOLAIR 150 mg, 9.8 from 17.1; placebo, 5.2 from 17.0).31

The difference in LS mean vs active control was 7.1 for XOLAIR 300 mg (P<0.001; 95% Cl: 9.3, 4.9) and 4.5 for XOLAIR 150 mg (P<0.001; 95% Cl: 6.7, 2.4)31

Hive Count: During Studies 1 and 2, the hive count score was measured twice a day (AM and PM) on a scale of 0 (no hives) to 3 (>12 hives). The daily hive count score was the average of the morning and evening scores, and the weekly hive count score (0-21) was the sum of the daily hive count scores over 7 days. 5

*Secondary efficacy endpoints across all studies included change from baseline in UAS7 at Week 12 and change from baseline in weekly hive count score at Week 12.

All patients received their dose of study drug or placebo in addition to stable doses of their prerandomization H1 antihistamine.5

UAS7=urticaria activity score over 7 days.

Complete Data

Study Designs

The safety and efficacy of XOLAIR for the treatment of CSU were assessed in 2 placebo-controlled, multiple-dose clinical studies of 24 weeks’ duration (CSU Study 1; N=319) and 12 weeks’ duration (CSU Study 2; N=322). Patients received XOLAIR 300 mg, 150 mg, 75 mg, or placebo in addition to their baseline level of H1 antihistamine therapy. The 75-mg dose is not approved for use. 1 Concomitant CSU treatments other than H1 antihistamines were not allowed during the study. 1,35,36

Complete Relief may be Possible for Your Patients

More than 1/3 of patients on XOLAIR 300 mg experienced complete relief, based on decreases in mean weekly itch severity and hive count scores

Percentage of patients achieving complete relief at Week 12 5,31
Image showing clinical study results, Percent of CSU Patients Achieving Complete Relief at Week 12.

Complete relief defined as: No itch and no hives (UAS7=0) at Week 12 (N=241).

XOLAIR for CSU is dosed at 300 mg or 150 mg every 4 weeks. See full dosing information.

Image showing a side-by-side comparison of CSU hives before and after XOLAIR treatment

UAS7: Understanding the Urticaria Activity Score (UAS)

The UAS Is a Composite Score of Itch Severity and Hive Count1,5

  • To assess disease severity in patients with CSU, patients record the severity of their itch and the number of hives twice daily (morning and evening). Their daily itch severity/hive count scores are an average of their morning and evening scores.
  • Each component of the UAS is scored on a scale of 0 to 3 (0=none to 3=intense/severe); the 2 scores are added together for a daily total of 0 to 6.
Urticaria Activity Score5,34
Data table chart showing the Urticaria Activity Score's daily scoring scale.

The UAS7 Is the Sum of the Average Daily UAS Over 7 Days1,5

  • After 7 days, average daily scores from the morning and evening assessments are added together.
    • Values can range between 0 and 21 for weekly itch severity, and 0 to 21 for weekly hive count.
  • The UAS7 ranges from 0 to 42.

In XOLAIR CSU clinical trials, disease severity was measured by the UAS7—which helped determine the primary efficacy endpoint.1,34

  • Disease severity was measured by the UAS7 (range, 0-42)—a composite of the weekly itch severity score (range, 0-21) and the weekly hive count score (range, 0-21).1
  • All patients were required to have a UAS7 of ≥16 and a weekly itch severity score of ≥8 for the 7 days prior to randomization, despite having used an H1 antihistamine for at least 2 weeks.1

Adverse Reactions Occurring in ≥2% in XOLAIR-treated Patients and More Frequently Than in Patients Treated With Placebo (Day 1 to Week 12) in CSU Trials

 Most common adverse reactions in CSU patients
Patient Baseline Characteristics

Studied Across a Broad Range of Patients

On average, prior to enrolling in Studies 1 and 2 (N=640), patients1,5,31,34

  • Experienced symptoms for 6.5-6.9 years after CSU diagnosis
  • Had already tried 4.3-4.7 CSU medications without adequate relief

~50% of patients in Studies 1 and 2 received steroids prior to enrollment.

XOLAIR Clinical Trial, Baseline Characteristics of Demographic Information, Medical History, and Severity of Asthma

IMPORTANT SAFETY INFORMATION

INDICATIONS
XOLAIR® (omalizumab) is indicated for:

  • Adults and pediatric patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

    Limitations of Use: XOLAIR is not indicated for the relief of acute bronchospasm, status asthmaticus, or for treatment of other allergic conditions.

  • Add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

  • Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment.

    Limitations of Use: XOLAIR is not indicated for treatment of other forms of urticaria.

WARNING: Anaphylaxis

Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis.

CONTRAINDICATIONS

XOLAIR is contraindicated in patients with a severe hypersensitivity reaction to XOLAIR or to any ingredient of XOLAIR.

WARNINGS AND PRECAUTIONS

Anaphylaxis
Anaphylaxis has been reported to occur after administration of XOLAIR in premarketing clinical trials and in postmarketing spontaneous reports. In premarketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3507 (0.1%) patients. Anaphylaxis occurred with the first dose of XOLAIR in two patients and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient.

A case-control study showed that, among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis.

In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006. Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of XOLAIR, with additional cases occurring sporadically beyond the third dose.

Initiate XOLAIR only in a healthcare setting equipped to manage anaphylaxis which can be life-threatening. Observe patients closely for an appropriate period of time after administration of XOLAIR, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs or symptoms occur.

Once XOLAIR therapy has been established, administration of XOLAIR Prefilled Syringe outside of a healthcare setting by a patient or a caregiver may be appropriate for selected patients. Patient selection, determined by the healthcare provider in consultation with the patient, should take into account the pattern of anaphylaxis events seen in premarketing clinical trials and postmarketing spontaneous reports, as well as individual patient risk factors (e.g. prior history of anaphylaxis), ability to recognize signs and symptoms of anaphylaxis, and ability to perform subcutaneous injections with XOLAIR Prefilled Syringe with proper technique according to the prescribed dosing regimen and Instructions for Use.

Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction.

Malignancy
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of adults and adolescents (≥12 years of age) with asthma and other allergic disorders. The observed malignancies in XOLAIR-treated patients were a variety of types, with breast, non-melanoma skin, prostate, melanoma, and parotid occurring more than once, and five other types occurring once each. The majority of patients were observed for less than 1 year. The impact of longer exposure to XOLAIR or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known.

A subsequent 5-year observational study of 5007 XOLAIR-treated and 2829 non-XOLAIR-treated adolescent and adult patients with moderate to severe persistent asthma and a positive skin test reaction or in vitro reactivity to a perennial aeroallergen found that the incidence rates of primary malignancies (per 1000 patient years) were similar in both groups (12.3 vs 13.0, respectively). Study limitations which include the observational study design, the bias introduced by allowing enrollment of patients previously exposed to XOLAIR (88%), enrollment of patients (56%) while a history of cancer or a premalignant condition were study exclusion criteria, and the high study discontinuation rate (44%) preclude definitively ruling out a malignancy risk with XOLAIR.

Acute Asthma Symptoms and Deteriorating Disease
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with XOLAIR.

Corticosteroid Reduction
Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of XOLAIR therapy for asthma or nasal polyps. Decrease corticosteroids gradually under the direct supervision of a physician. In CSU patients, the use of XOLAIR in combination with corticosteroids has not been evaluated.

Eosinophilic Conditions
In rare cases, patients with asthma on therapy with XOLAIR may present with serious systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome. These events usually, but not always, have been associated with the reduction of oral corticosteroid therapy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between XOLAIR and these underlying conditions has not been established.

Fever, Arthralgia, and Rash
In post-approval use, some patients have experienced a constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy with an onset 1 to 5 days after the first or subsequent injections of XOLAIR. These signs and symptoms have recurred after additional doses in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.

Parasitic (Helminth) Infection
Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.

Laboratory Tests
Due to formation of XOLAIR:IgE complexes, serum total IgE levels increase following administration of XOLAIR and may remain elevated for up to 1 year following discontinuation of XOLAIR. Do not use serum total IgE levels obtained less than 1 year following discontinuation to reassess the dosing regimen for asthma or nasal polyps patients, because these levels may not reflect steady state free IgE levels.

ADVERSE REACTIONS

Asthma
In patients ≥12 years of age, the most common adverse reactions (≥1% more frequent in XOLAIR-treated patients) were: arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). In pediatric patients 6 to <12 years of age, the most commonly observed adverse reactions (≥3% more frequent in XOLAIR-treated pediatric patients) were: nasopharyngitis, headache, pyrexia, upper abdominal pain, pharyngitis streptococcal, otitis media, viral gastroenteritis, arthropod bite, and epistaxis.

Nasal Polyps
The most common adverse reactions (≥3% incidence in XOLAIR-treated patients and more frequent than placebo) included: headache (8.1%), injection site reaction (5.2%), arthralgia (3.0%), upper abdominal pain (3.0%), and dizziness (3.0%).

Chronic Spontaneous Urticaria
The most common adverse reactions (≥2% XOLAIR-treated patients and more frequent than in placebo) for XOLAIR 150 mg and 300 mg, respectively, included: headache (12%, 6%), nasopharyngitis (9%, 7%), arthralgia (3%, 3%), viral upper respiratory infection (2%, 1%), nausea (1%, 3%), sinusitis (1%, 5%), upper respiratory tract infection (1%, 3%), and cough (1%, 2%).

Injection Site Reactions

Asthma
In adults and adolescents with asthma, injection site reactions of any severity occurred at a rate of 45% in XOLAIR-treated patients compared with 43% in placebo-treated patients. Severe injection site reactions occurred more frequently in XOLAIR‑treated patients compared with patients in the placebo group (12% vs 9%, respectively). The types of injection site reactions in asthma studies included: bruising, redness, warmth, burning, stinging, itching, hive formation, pain, indurations, mass, and inflammation.

Nasal Polyps
Injection site reactions occurred at a rate of 5.2% in XOLAIR-treated patients compared with 1.5% in placebo-treated patients. Injection site reactions were mild to moderate severity and none resulted in study discontinuation.

Chronic Spontaneous Urticaria
Injection site reactions of any severity occurred in more XOLAIR-treated patients (11 patients [2.7%] at 300 mg, 1 patient [0.6%] at 150 mg) compared with 2 placebo-treated patients (0.8%). The types of injection site reactions included: swelling, erythema, pain, bruising, itching, bleeding, and urticaria. None of the events resulted in study discontinuation or treatment interruption.

Cardiovascular and Cerebrovascular Events from Clinical Studies in Patients with Asthma
A 5-year observational study was conducted in 5007 XOLAIR-treated and 2829 non-XOLAIR-treated patients ≥12 years of age with moderate to severe persistent asthma and a positive skin test reaction to a perennial aeroallergen to evaluate the long term safety of XOLAIR, including the risk of malignancy. Similar percentages of patients in both cohorts were current (5%) or former smokers (29%). Patients had a mean age of 45 years and were followed for a mean of 3.7 years. More XOLAIR-treated patients were diagnosed with severe asthma (50%) compared to the non-XOLAIR-treated patients (23%). A higher incidence rate (per 1000 patient-years) of overall cardiovascular and cerebrovascular serious adverse events (SAEs) was observed in XOLAIR-treated patients (13.4) compared to non-XOLAIR-treated patients (8.1). Increases in rates were observed for transient ischemic attack (0.7 vs 0.1), myocardial infarction (2.1 vs 0.8), pulmonary hypertension (0.5 vs 0), pulmonary embolism/venous thrombosis (3.2 vs 1.5), and unstable angina (2.2 vs 1.4), while the rates observed for ischemic stroke and cardiovascular death were similar among both study cohorts. The results suggest a potential increased risk of serious cardiovascular and cerebrovascular events in patients treated with XOLAIR, however the observational study design, the inclusion of patients previously exposed to XOLAIR (88% for a mean of 8 months), baseline imbalances in cardiovascular risk factors between the treatment groups, an inability to adjust for unmeasured risk factors, and the high study discontinuation rate (44%) limit the ability to quantify the magnitude of the risk.

Pregnancy
Data with XOLAIR use in pregnant women are insufficient to inform on drug associated risk.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.

Please see full Prescribing Information, including Boxed WARNING and Medication Guide, for additional Important Safety Information.

    • XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.

      XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.

    • Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.

      Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.

    • Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/

      Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/

    • World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.

      World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.

    • Data on file. Genentech USA, Inc. South San Francisco, CA.

      Data on file. Genentech USA, Inc. South San Francisco, CA.

    • Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

      Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

    • Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.

      Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.

    • Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.

      Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.

    • Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.

      Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.

    • Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.

      Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.

    • Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.

      Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.

    • Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.

      Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.

    • Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.

      Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.

    • Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

      Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

    • Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.

      Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.

    • Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.

      Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.

    • National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.

      National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.

    • Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.

      Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.

    • Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.

      Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.

    • Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/2315/immunocap-ref-range_test-menu_0318.pdf. Accessed March 19, 2020.

      Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/2315/immunocap-ref-range_test-menu_0318.pdf. Accessed March 19, 2020.

    • Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.

      Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.

    • Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.

      Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.

    • Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.

      Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.

    • Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.

      Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.

    • Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.

      Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.

    • Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.

      Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.

    • Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.

      Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.

    • Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.

      Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.

    • Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.

      Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.

    • Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.

      Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.

    • Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.

      Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.

    • Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.

      Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.

    • Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.

      Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.

    • Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.

      Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.

    • Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.

      Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.

    • US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.

      US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.

      • XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.

        XOLAIR [prescribing information]. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation; 2021.

      • Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.

        Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.

      • Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/

        Allergens and allergic asthma. Asthma and Allergy Foundation of America. Accessed August 11, 2021. https://www.aafa.org/allergic-asthma/

      • World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.

        World Health Organization. Prevention of allergy and allergic asthma. Based on the WHO/WAO meeting on the prevention of allergy and allergic asthma; January 8-9, 2002; Geneva, Switzerland.

      • Data on file. Genentech USA, Inc. South San Francisco, CA.

        Data on file. Genentech USA, Inc. South San Francisco, CA.

      • Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

        Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-lgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.

      • Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.

        Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254-261.

      • Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.

        Chipps BE, Zeiger RS, Luskin AT, et al. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol. 2017;119(6):524-532.e2.

      • Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.

        Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013;13(1):78-86.

      • Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.

        Comberiati P, McCormack K, Malka-Rais J, Spahn JD. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma. J Allergy Clin Immunol Pract. 2019;7(8):2689-2696.e2.

      • Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.

        Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918-927.

      • Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.

        Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases. Curr Opin Pharmacol. 2019;46:100-107.

      • Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.

        Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.

      • Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

        Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704.

      • Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.

        Akdis CA, Arkwright PD, Brüggen M-C, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582-1605.

      • Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.

        Siles RI, Hsieh FH. Allergy blood testing: a practical guide for clinicians. Cleve Clin J Med. 2011;78(9):585-592. doi:10.3949/ccjm.78a.11023.

      • National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.

        National Heart, Lung, and Blood Institute of Health; 2007. NIG publication 07-4051.

      • Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.

        Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3)(Suppl 3):S1-S148.

      • Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.

        Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Clinical management review: allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8:429-440.

      • Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/
        2315/immunocap-ref-range_test-menu_0318.pdf.
        Accessed March 19, 2020.

        Sonora Quest Laboratories. Test Interpretation and Management Options—Utilizing ImmunoCAP®’ KU/L Results. https://www.sonoraquest.com/media/
        2315/immunocap-ref-range_test-menu_0318.pdf.
        Accessed March 19, 2020.

      • Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.

        Kerkhof M, Dubois AE, Postma DS, et al. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003;58(9):905-911.

      • Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.

        Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490-497.

      • Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.

        Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2007;120(5):1139-1145.

      • Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.

        Reddel HK, Taylor DR, Bateman ED, et al; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1):59-99.

      • Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.

        Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210-1216.

      • Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.

        Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163-169.

      • Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.

        Global Initiative for Asthma (GINA). What’s new in GINA 2021? GINA global strategy for asthma management and prevention.

      • Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.

        Global Initiative for Asthma. Global strategy for asthma management and prevention, 2021.

      • Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.

        Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. J All Clin Immunol. 2020;145(2):528-536.e1.

      • Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.

        Census Bureau Projects U.S. Population of 317.3 Million on New Year's Day [press release]. Washington, DC: U.S. Census Bureau; December 30, 2013.

      • Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.

        Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report [published online November 17, 2010]. Allergy. 2011;66(3):317-330. doi:10.1111/j.1398-9995.2010.02496.x.

      • Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.

        Grattan CEH. Urticaria and angioedema. In: Bolognia JL, Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012:291-306.

      • Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.

        Hoskin B, Ortiz B, Paknis B, Kavati A. Exploring the real-world profile of refractory and non-refractory chronic idiopathic urticaria in the USA: clinical burden and healthcare resource use. Curr Med Res Opin. 2019;35(8):1387-1395.

      • Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.

        Roche. FDA approves Xolair (omalizumab) for people with chronic idiopathic urticaria, a form of chronic hives. https://www.roche.com/media/releases/med-cor-2014-03-24.htm. March 2014. Accessed January 14, 2021.

      • Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.

        Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study [published correction appears in J Invest Dermatol. 2015;135(3):925. doi:10.1038/jid.2014.512]. J Invest Dermatol. 2015;135(1):67-75. doi:10.1038/jid.2014.306.

      • US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.

        US Department of Health and Human Services. Determination that astemizole 10-milligram tablets were withdrawn from sale for safety reasons. Federal Register. 1999;64(162):45973-45974.